Roivant Sciences (ROIV) Current Deferred Revenue (2021 - 2025)

Roivant Sciences (ROIV) has reported Current Deferred Revenue for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue fell 71.98% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2025 stood at $1.2 million (down 71.98% YoY), and the FY2025 full-year result was $1.2 million, down 71.98% from the prior year.
• Current Deferred Revenue fell to $1.2 million in Q1 2025 per ROIV's latest filing, from $3.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $12.4 million in Q1 2023 and bottomed at $1.2 million in Q1 2025.
• Historically, Current Deferred Revenue has averaged $6.4 million across 5 years, with a median of $5.9 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue soared 71.46% in 2022, then sank 74.83% in 2024.
• Over 5 years, Current Deferred Revenue stood at $5.9 million in 2021, then soared by 31.73% to $7.8 million in 2022, then sank by 39.78% to $4.7 million in 2023, then tumbled by 35.31% to $3.0 million in 2024, then slumped by 61.54% to $1.2 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $1.2 million, $3.0 million, and $3.4 million for Q1 2025, Q4 2024, and Q3 2024 respectively.